Clinical Trials

According to the International Clinical Trials Registry Platform under the World Health Organization (WHO) and clinicaltrials.gov under the U.S. National Institutes of Health the following trials should be recruiting at this moment (updated 26 June 2020):

• A Long Term Safety Study of BCX7353 in HAE (APeX-S) – recruiting in Australia, Austria, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, South Korea, New Zealand, North Macedonia, Poland, Serbia, Slovakia, South Africa, Spain, Switzerland, the United Kingdom, and the United States of America
  

  ---

• A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With HAE Type I or II – recruiting in Austria, Czech Republic, Germany, Hungary, Italy, the Netherlands, North Macedonia, Poland, the United Kingdom, and the United States of America
  

  ---

• A Study to Assess the Clinical Efficacy of IONIS-PKKLRx in Participants with HAE – recruiting in the United States of America
  

  ---

• A Study to Investigate CSL312 in Subjects with HAE – recruiting in Australia, Canada, Germany, Israel, and the United States of America
  

  ---

• An Extension Study of IONIS-PKK-LRx in Participants with HAE – recruiting in the United States of America
  

  ---

• Biomarker for HAE Disease – recruiting in Georgia and Romania
  

  ---

• C1 Inhibitor Registry in the Treatment of HAE Attacks – recruiting in Bulgaria, Croatia, Czech Republic, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, and Sweden
  

  ---

• Cloud-R HAE Registry (CloudRHAE) – recruiting in France
  

  ---

• Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE – recruiting in the United States of America
  

  ---

• Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population (BRADYKID) – recruiting in France
  

  ---

• Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants with HAE – recruiting in Japan
  

  ---

• Epidemiological Analysis for HAE Disease (EHA) – recruiting in Germany, Italy, Japan, Poland, Turkey, and the United Kingdom
  

  ---

• Firazyr General Drug Use-Results Survey (Japan) – recruiting in Japan
  

  ---

• Firazyr Patient Registry (Icatibant Outcome Survey – IOS) – recruiting in Australia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Spain, Sweden, and the United Kingdom
  

  ---

• Global Registry to Gather Data on Natural History of Patients with HAE Type I and II – recruiting in Italy
  

  ---

• HAE Kininogen Assay (HAEKA) – recruiting in Germany
  

  ---

• Patient Registry to Evaluate the Real-world Safety of Ruconest – recruiting in the United States of America
  

  ---

• Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants with HAE – recruiting in Canada, Puerto Rico, and the United States of America
  

  ---

• Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants with HAE – recruiting in Austria, Germany, Switzerland, and the United Kingdom
  

  ---

• The Role of the Coagulation Pathways in Recurrent Angioedema (Angiocoag) – recruiting in France
  

  ---

Read more about these and other clinical trials at https://clinicaltrials.gov and http://apps.who.int/trialsearch.